This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Dextrorphan: Difference between revisions
>ExistingEntity Added some significant binding affinities to pharmacology section |
>ExistingEntity Cleanup; multiple changes |
||
| Line 8: | Line 8: | ||
==Chemistry== | ==Chemistry== | ||
[[ | Dextrorphan is a dextrorotatory molecule of the morphinan class. It contains a phenanthrene core structure with one aromatic ring (benzene) bound to two saturated rings (cyclohexane).[[Dextromethorphan]] is metabolized in the body by o-demethylation through the CYP2D6 enzyme to form Dextrorphan.<ref>Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. [https://www.ncbi.nlm.nih.gov/pubmed/1306804]</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
The pharmacology of dextrorphan is similar to that of dextromethorphan (DXM). However, dextrorphan is much more potent as an [[NMDA receptor antagonist]] as well as essentially inactive as a [[serotonin]] [[reuptake inhibitor]].<ref>Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism: A Pilot Study [http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=1998&issue=08000&article=00014&type=abstract]</ref> | The pharmacology of dextrorphan is similar to that of dextromethorphan (DXM). However, dextrorphan is much more potent as an [[NMDA receptor antagonist]] as well as essentially inactive as a [[serotonin]] [[reuptake inhibitor]].<ref>Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism: A Pilot Study [http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=1998&issue=08000&article=00014&type=abstract]</ref> DXO is an active chemical and contributes to the [[DXM#Subjective effects|subjective effects]] experienced when active doses of DXM are consumed.<ref>Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders - 3. Pharmacodynamics (January 2016)[https://www.researchgate.net/publication/292212463_Dextromethorphan_An_update_on_its_utility_for_neurological_and_neuropsychiatric_disorders]</ref> | ||
===Binding affinities (K<sub>i</sub>)=== | ===Binding affinities (K<sub>i</sub>)=== | ||
| Line 59: | Line 59: | ||
==Legal issues== | ==Legal issues== | ||
{{legalStub}} | |||
* '''Germany:''' Not controlled | * '''Germany:''' Not controlled | ||
* '''Poland:''' Unscheduled<ref>List of scheduled substances in Poland. | * '''Poland:''' Unscheduled<ref>List of scheduled substances in Poland. | ||